purinostat mesylate (Guizhou Bailing Group Pharmaceutical/West China Hospital)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namepurinostat mesylate (Guizhou Bailing Group Pharmaceutical/West China Hospital)
Drug Alias Namepreisinastat mesylatepremilastat mesilatePrexostat mesylatepurinostat mesylate (Chengdu Zeling Biomedical Technology)
ClassificationSmall molecules
Mechanisms of ActionHistone deacetylase inhibitors
TargetsHistone deacetylase
Therapy Area/IndicationsBone metastasesMetastatic breast cancerSolid tumours +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWest China Hospital Of Sichuan University
China Registration ClassN/A

Develop Information

Active CompaniesChengdu Zenitar Biomedical Technology Co LtdGuizhou Bailing Group Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsBone metastasesMetastatic breast cancerSolid tumours +[19] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A